Myriad Genetics Inc (MYGN) Com Stk USD0.01

Sell:$14.56Buy:$14.58$0.09 (0.61%)

NASDAQ:0.41%
Market closed | Prices delayed by at least 15 minutes
Sell:$14.56
Buy:$14.58
Change:$0.09 (0.61%)
Market closed | Prices delayed by at least 15 minutes
Sell:$14.56
Buy:$14.58
Change:$0.09 (0.61%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight, among others.

Key people

Paul J. Diaz
President, Chief Executive Officer, Director
Scott J. Leffler
Chief Financial Officer
George Daneker
President, Chief Clinical Officer - Oncology
Sam Raha
Chief Operating Officer
Shereen Solaiman
Chief People Officer
Margaret Ancona
Senior Vice President, Chief of Staff
Kevin R. Haas
Chief Technology Officer
Dale Muzzey
Chief Scientific Officer
Jennifer Fox
Chief Legal Officer
Mark S. Verratti
Chief Commercial Officer
S. Louise Phanstiel
Independent Chairman of the Board
Paul M. Bisaro
Independent Director
Mark S. Davis
Independent Director
Heiner Dreismann
Independent Director
Rashmi Kumar
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US62855J1043
  • Market cap
    $1.19bn
  • Employees
    2,700
  • Shares in issue
    91.04m
  • Exchange
    NASDAQ
  • Index
    S&P 600 Small Cap, TR Equity United States Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.